[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

32

1 variability.
2 So I presented that data actually not in
3 a contentious way with respect to at least my
4 interpretation of, quote, "rgp 160's" role there. It
5 is very clear that we don't get protection with BAC on
6 the long list of combinations that does do that. And
7 it is a very positive response on the basis of the
8 immunogen. The fact that I think it is lost over time
9 is something that I believe.
10 Now, I would also say to my knowledge that
11 the SCID use studies that were done were: A) Did it
12 use a different vaccination schema? And, number two,
13 is that the patients that were selected for protection
14 were the one that had the highest T cell responses in
15 the Mosier experiment.
16 To my knowledge, that was not done in the
17 NIAID experiment. We use it, again, as an example to
18 say that the immunogen may have a role and may have a
19 functional response.
20 So if you have misinterpreted my
21 interpretation of those data, I would say I think you
22 have.
NEAL R. GROSS
COURT REPORTERS AND TRANSCRISERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]